Efferon therapy

08/09/2026

Awareness Month: when becomes part of the answer

This month, leading up to (13 September), we'll share voices from clinicians on the front lines.

Dr. Rodoljub Marković, nephrologist at Clinical Hospital Centre Zemun, shares his experience treating severe sepsis cases. He talks about personalizing therapy based on what each patient needs, combining different treatment approaches rather than relying on a single protocol, and the role hemoadsorption can play when conventional treatment alone is not enough.

Our sincere thanks to Dr. Marković for taking the time to share his thoughts.

07/09/2026

Living through is a frightening and traumatic experience. Efferon LPS makes it shorter

LASSO study showed that Efferon LPS multimodal was associated with fewer ICU days and hospital days per patient.

Sepsis means days spent in an unfamiliar hospital environment, away from family and normal life. A shorter stay means less time in intensive care and getting home sooner, where life can start to feel a little more normal again.

Learn more at efferon.com!

02/09/2026

Efferon joins the World Sepsis Day discussion

On September 11, the Riga East University Hospital conference dedicated to World Sepsis Day will bring together specialists to discuss different aspects of sepsis care, from early recognition and pathogen identification to source control, refractory septic shock and the latest sepsis guidelines.

Ivan Bessonov, CTO and Co-Founder of Efferon, will give a talk “Endotoxin and Beyond: Rethinking Hemoadsorption in Sepsis”, looking at the role of next-generation multimodal hemoadsorption in the sepsis management.

Hemodynamic stabilization, faster resolution of septic shock, reduced inflammatory markers, shorter time on mechanical ventilation: Efferon delivers these outcomes, supporting clinical recovery when standard therapy alone isn't enough.

See you there!

31/08/2026

Efferon kaže "zdravo!" u Hrvatsku 🇭🇷

Efferon LPS is now registered for clinical use in Croatia, together with our partner Bertossi.

Croatia is not new territory for Efferon. We have already met the local intensive care community in Dubrovnik and Zagreb, presenting our technology and discussing clinical experience with next-generation multimodal hemoadsorption. Now the conversation can move from conference halls to clinical practice.

Croatia is another step in Efferon's growing presence across the Balkans and the wider Adriatic region. Looking forward to what comes next!

28/08/2026

Efferon вели „здраво“ во Северна Македонија! 🇲🇰

Efferon is now registered in North Macedonia, expanding our partnership with Medicon, which represents Efferon across the Balkan region.

Sepsis and septic shock leave little room for response. combines endotoxin and cytokine adsorption to address two key drivers of the systemic inflammatory response, giving time when it's needed. We look forward to bringing this experience to new teams and new countries.

🎉 North Macedonia is now on the map!

24/08/2026

Efferon is heading to TechCrunch Disrupt 2026!

TechCrunch has selected Efferon among 200 of the most promising early-stage startups from thousands of applications worldwide!

And this is only the beginning: in October, our CEO and co-founder Dima Romashin will take the stage in San Francisco to pitch Efferon and our approach to next-generation hemoadsorption.

Building a medical technology company means taking an idea from the lab all the way to real patients. Efferon has done that across dozens of countries. Now we’re taking that story to one of the biggest stages in tech.

📍 October 13–15. San Francisco. See you at Disrupt!

We’re thrilled to unveil the 2026 Startup Battlefield 200, our annual handpicked list of the 200 most promising early-stage startups from around the world.

21/08/2026

Multimodal changes the game, combining and removal in a single solution. See how it works.

19/08/2026

Efferon got the spotlight at the Nephrology Society of Thailand Annual Conference in Bangkok last week.

In Thailand, nearly 4 in 10 patients with die. When the patient develops septic shock, the risk is even higher. That’s why we’re here. was only approved in Thailand in February, and our partner NorrDia AB is building awareness in a region where hemoadsorption still isn’t part of standard critical care practice.

Together, we can change that. What was clear from is that physicians are looking for a therapy that simultaneously removes both and .

Thanks to the NorrDia AB team for trusting us to do this work together.

12/08/2026

We are giving time!

This is how Efferon CEO and co-founder Dima Romashin describes the role of blood purification in : buying time for critically ill patients while antibiotics and other treatments address the underlying infection.

A new Tech.eu feature looks at the science behind Efferon’s approach, our clinical evidence, and the development of Efferon LPS and Efferon NEO. Today, Efferon technology has been used in more than 25,000 treatments across 44 countries.

Read the full story in Tech.eu: https://tech.eu/2026/08/11/efferon-is-selling-time-in-the-race-to-treat-sepsis/

The Austrian medtech is using multimodal blood purification to tackle sepsis and septic shock, with devices for adult and pediatric intensive care.

11/08/2026

Shorter ICU stays aren't just a clinical win. They free up resources, reduce costs, and let patients go home sooner.

This is what Efferon does.
See the data above and learn more at efferon.com!